Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

In a turbulent market environment, Frequency Therapeutics Inc (KRRO) stock has been under significant pressure, touching a 52-week low of $18.42, marking a dramatic 81% decline from its 52-week high ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

For example, biotech and mining... CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

Read Our Latest Stock Report on KRRO Korro Bio Trading Up 1.1 % KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23 ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of ...

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...